PremiumJANX

Sharp decline creates interest

JANX stock plummeted sharply after the publication of phase 1 trial data, but the clinical data remained positive.

By the SpyStocks desk · 8mo ago · 1 min read

The rest of this story is for members

The rest is for members

The story continues: the full timeline, the transaction ranges, and the names the forms carry.

Premium comes through the Telegram channel. Already have a code? Sign in to activate it.

Telegram@TheAmericanDream5

Real-time buys, sweeps, and trading halts from the desk. Free to join.